Current Issue

HIGHLIGHTS

  • Skin barrier damage and itch
    Gil Yosipovitch, Laurent Misery, Ehrhardt Proksch, Martin Metz, Sonja Ständer, Martin Schmelz
  • A summary of research and current opinion on available topical therapies for itch and recommendations for the optimal management.
  • Patient-reported outcomes in psoriasis
    Nikolai Dyrberg Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, Lars Erik Bryld, Robert Gniadecki, Tomas Norman Dam, Lars Iversen, Lone Skov
  • Measuring and monitoring of patients' symptoms are important, and additional measures to capture symptoms might be beneficial in daily practice.
  • Characteristics of mycosis fungoides and Sézary syndrome
    Pia Rude Nielsen, Jens Ole Eriksen, Ulrike Wehkamp, Lise Maria Lindahl, Robert Gniadecki, Hanne Fogh, Susanne Fabricius, Michael Bzorek, Niels Ødum, Lise Mette Rahbek Gjerdrum
  • This study describes all aspects of clinical and histopathological findings in patients with mycosis fungoides and Sézary syndrome in a well-characterized Danish cohort.
  • Botulinum toxin injections in axillary hyperhidrosis: a 15-year study
    Clémence Berthin, Hervé Maillard
  • Repeated botulinum toxin A injections lead to an increase in duration of efficacy without secondary decrease.
  • Tumour volume doubling times – periocular and other BCCs
    Andre Boo Shern Khoo, Patrick Kin Yoong Goon, Holger Sudhoff, Peter Kin Cho Goon
  • These new data can guide clinicians as to how much time there is available for removal or treatment before crucial parts of our anatomy could be affected.
  • Patch testing with isobornyl acrylate in contact dermatitis patients from insulin pumps
    Martin Mowitz, Louise Fornander, Sara Hosseiny, Kristina Ryberg, Magnus Bruze
  • In this report the results from patch testing with isobornyl acrylate in 4 Swedish dermatology clinics is presented.
  • Atopic dermatitis-like eruption induced by biologics in psoriatic arthritis patient
    Fumihito Abe, Shinji Mitsuyama, Eri Nagao, Masaaki Kimura, Tetsuya Higuchi
  • A patient with psoriatic arthritis who developed atopic dermatitis-like eruptions caused by the separate administration of 2 types of biologics, infliximab and ixekizumab, is described.
  • Possible paradoxical photosensitive psoriasis induced by TNF-alpha inhibi
    Pauline Bataille, Adèle De Masson, Marie-Dominique Vignon-Pennamen, Jean-David Bouaziz, Jean-Marc Gornet
  • Un unusual case of sun-induced paradoxical psorisis in an adult patient treated with infliximab for Crohn's disease.

    Quiz

    QUIZ - 2020-02-05
    Patches, Bumps, Purplish Macules and Papules in a Patient with Pruritus: A Quiz
    XiaoXiao Yan, MeiLing Yu, GuiZhi Zhou, FuRen Zhang
    QUIZ - 2020-01-07
    Uncountable Skin Lesions in a Mentally Disabled Patient: A Quiz
    Iwona Chlebicka, Aleksandra Stefaniak, Karolina Wójcicka, Jacek C. Szepietowski
    Show more quizzes »

    This is ActaDV

    An international peer-reviewed journal for clinical and experimental research in the field of dermatology and venereology.

    Published by the Non-Profit Organization Society for Publication of Acta Dermato-Venereologica

    The official Journal of:
    European Society for Dermatology and Psychiatry

    Affiliated with:
    International Forum for the Study of Itch

    Go to Content »

    ISI Impact Factor 2018: 3.531 H Index: 75

    SCImago Journal & Country Rank
    Sign up for e-mail alerts and be notified when the next issue is released.


    By sending this form you confirm that your personal data will be stored with regards to the privacy policy.

    From current issue: 13 (99)

    CLINICAL REPORT
    Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study
    Nikolai Dyrberg Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, Lars Erik Bryld, Robert Gniadecki, Tomas Norman Dam, Lars Iversen, Lone Skov
    This registry study from DERMBIO demonstrate weak-to-moderate correlations between PASI and DLQI during a 5-year period and between changes in PASI and DLQI in patients treated with biologics or apremilast. Of all the questions of the DLQI, the first question on “Symptoms and feelings” was the one contributing most to the overall DLQI and this increased over time. The results of this study show that some of the questions of the DLQI might be redundant and additional measures to capture subjective symptoms might be beneficial in future studies and daily practice.
    Pages: 1224-1230
    SHORT COMMUNICATION
    Atopic Dermatitis-like Eruption Induced by Two Different Biologics in a Patient with Psoriatic Arthritis
    Fumihito Abe, Shinji Mitsuyama, Eri Nagao, Masaaki Kimura, Tetsuya Higuchi
    We experienced a patient with psoriatic arthritis who developed atopic dermatitis-like eruptions caused by administration of two different types of biologics, infliximab and ixekizumab. Skin biopsy revealed epidermal spongiosis and lymphocyte perivascular infiltration in upper dermis. It is suggested that atopic dermatitis-like eruptions are not a skin disorder specific to a drug but might occur in patients with psoriasis treated with any biologics. A possible reason for the development of atopic dermatitis-like eruptions is transition from Th1 to Th2 dominance by biologics.
    Pages: 1291-1292
    Volume 93, Issue 3
    REVIEW
    Skin pH: From Basic SciencE to Basic Skin Care
    Saba M. Ali, Gil Yosipovitch
    Volume 95, Issue 1
    SPECIAL REPORT
    Evidence-based Danish Guidelines for the Treatment of Malassezia-related Skin Diseases
    Marianne Hald, Maiken C. Arendrup, Else L. Svejgaard, Rune Lindskov, Erik K. Foged, Ditte Marie L. Saunte
    Volume 92, Issue 5
    SPECIAL REPORT
    European Guideline on Chronic Pruritus
    Elke Weisshaar, Jacek C. Szepietowski, Ulf Darsow, Laurent Misery, Joanna Wallengren, Thomas Mettang, Uwe Gieler, Torello Lotti, Julien Lambert, P. Maisel, Markus Streit, Malcolm W. Greaves, Andrew J. Carmichael, Erwin Tschachler, Johannes Ring, Sonja Ständer
    Volume 95, Issue 2
    SHORT COMMUNICATION
    Efficacy of Fluconazole at a 400 mg Weekly Dose for the Treatment of Onychomycosis
    Anita Hryncewicz-Gwóźdź, Ewa Plomer-Niezgoda, Katarzyna Kalinowska, Anna Czarnecka, Joanna Maj, Tomasz Jagielski
    2020-02-10
    INVESTIGATIVE REPORT
    Increased Expression of Delta-like Ligand 4 in Mycosis Fungoides
    Hikari Boki, Tomomitsu Miyagaki, Yuki Shono, Hiroaki Kamijo, Tomonori Oka, Hiraku Suga, Yoshihide Asano, Makoto Sugaya, Shinichi Sato
    2020-02-10
    QUIZ
    Myxoid Nodule on the Leg of an Immunosuppressed Man: A Quiz
    Fouad Mitri, Julia Hartmann, Thomas Mentzel, Alexander Enk, Ferdinand Toberer
    2019-02-27
    ERRATUM
    Erratum